Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
0.5887
-0.0302 (-4.88%)
At close: May 9, 2025, 4:00 PM
0.5900
+0.0013 (0.22%)
After-hours: May 9, 2025, 7:38 PM EDT
Nektar Therapeutics Employees
Nektar Therapeutics had 61 employees as of December 31, 2024. The number of employees decreased by 76 or -55.47% compared to the previous year.
Employees
61
Change (1Y)
-76
Growth (1Y)
-55.47%
Revenue / Employee
$1,430,295
Profits / Employee
-$2,181,000
Market Cap
109.56M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 94,300 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
NKTR News
- 1 day ago - Nektar Therapeutics (NKTR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 1 day ago - Nektar Therapeutics Reports First Quarter 2025 Financial Results - PRNewsWire
- 8 days ago - Nektar to Announce Financial Results for the First Quarter on Thursday, May 8, 2025, After Close of U.S.-Based Financial Markets - PRNewsWire
- 7 weeks ago - Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - PRNewsWire
- 2 months ago - Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 2 months ago - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets - PRNewsWire
- 2 months ago - Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata - PRNewsWire